About: 25E-NBOH

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in Slovenia. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors.

Property Value
dbo:abstract
  • 25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in Slovenia. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors. (en)
dbo:casNumber
  • 1391489-79-4
  • 1539266-40-4
dbo:fdaUniiCode
  • EB0KU6R3BE
dbo:pubchem
  • 135391539
dbo:thumbnail
dbo:wikiPageID
  • 65845629 (xsd:integer)
dbo:wikiPageLength
  • 3832 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1095944586 (xsd:integer)
dbo:wikiPageWikiLink
dbp:c
  • 19 (xsd:integer)
dbp:casNumber
  • 1391489 (xsd:integer)
  • 1539266 (xsd:integer)
dbp:h
  • 25 (xsd:integer)
dbp:index2Label
dbp:iupacName
  • 2 (xsd:integer)
dbp:legalDe
  • NpSG (en)
dbp:legalUk
  • Class A (en)
dbp:n
  • 1 (xsd:integer)
dbp:o
  • 3 (xsd:integer)
dbp:pubchem
  • 135391539 (xsd:integer)
dbp:smiles
  • CCC1=CCOC (en)
dbp:stdinchi
  • 1 (xsd:integer)
dbp:stdinchikey
  • SYBINTRPEZWFLZ-UHFFFAOYSA-N (en)
dbp:unii
  • EB0KU6R3BE (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • 25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in Slovenia. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors. (en)
rdfs:label
  • 25E-NBOH (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License